Ultrapetrol (Bahamas) Limited (NASDAQ:ULTR) shares increased 5.00% in last trading session and ended the day at $0.21. ULTR Gross Margin is 28.30% and its has a return on assets of -5.60%. Ultrapetrol (Bahamas) Limited (NASDAQ:ULTR) quarterly performance is -44.74%.
On 7 March, Ultrapetrol (Bahamas) Limited (NASDAQ:ULTR) announced the appointments of Mr. Barry W. Ridings and Mr. John C. Wobensmith to the Company’s Board of Directors. The additions of Mr. Ridings and Mr. Wobensmith will increase the Board’s membership to seven.
On 09 March, Caterpillar Inc. (NYSE:CAT) shares advanced 0.20% and was closed at $71.87. CAT EPS growth in last 5 year was -3.30%. Caterpillar Inc. (NYSE:CAT) year to date (YTD) performance is 7.08%.
Caterpillar Inc. (NYSE:CAT) and SunSelect Produce Inc., a Canadian company known for producing premium greenhouse-grown vegetables for more than 30 years, this week announced a strategic collaboration.
Facebook Inc (NASDAQ:FB) shares advanced 1.49% in last trading session and ended the day at $107.51. FB Gross Margin is 84.00% and its has a return on assets of 8.10%. Facebook Inc (NASDAQ:FB) quarterly performance is 1.80%.
On 5 March, Facebook Inc (NASDAQ:FB) plans to open up its messaging platform to developers later this year during its F8 developer conference, according to a new report in Marketing Land. The feature will allow publishers to share content through Messenger via chat bots, with short descriptions linking back to articles on their website, the report says.
Alphabet Inc (NASDAQ:GOOG) caters to the Technology space. Its weekly performance is -1.89%. On the last day of trading company shares ended up at $705.24. Alphabet Inc (NASDAQ:GOOG) distance from 50-day simple moving average (SMA50) is 1.92%.
On 4 March, Alphabet Inc (NASDAQ:GOOG) said that, company is extending the feature to the commercial realm and offering it to a select group of small businesses.
Cymabay Therapeutics, Inc. (NASDAQ:CBAY) caters to the Healthcare space. Its weekly performance is 14.77%. On the last day of trading company shares ended up at $1.32. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) distance from 50-day simple moving average (SMA50) is 80.17%.
Zacks Investment Research upgraded shares of CymaBay Therapeutics Inc (NASDAQ:CBAY)from a hold rating to a buy rating in a research report released on Wednesday morning,Marketbeat.com reports. Zacks Investment Research currently has $1.25 price objective on the biopharmaceutical company’s stock.
Leave a Reply